Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic reports insider transactions on September 3-4, 2026. Executive Vice President Russell Thirsk exercised warrants to subscribe for 28,590 shares at DKK 190.11 per share and immediately sold them at DKK 215.47 per share, realizing a profit of approximately DKK 725,277. Board member Anja Gjøl sold 345 shares at prices ranging from DKK 221.80 to DKK 222.00.

09/04/2026, 12:00 PM • GlobeNewswire

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer

Bavarian Nordic A/S reports insider transactions by key executives. Russell Thirsk, Executive Vice President and Chief Operating Officer, exercised 28,590 warrants at DKK 190.11 per share and subsequently sold all 28,590 shares at DKK 215.47 per share on September 4, 2026. Board member Anja Gjøl sold 345 shares at prices ranging from DKK 221.80 to DKK 222.00 on September 3, 2026.

09/04/2026, 12:00 PM • GlobeNewswire

Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner

Bavarian Nordic A/S announced a capital increase of DKK 285,900 following employees' exercise of subscription options. The company issued 28,590 new shares at DKK 190.11 per share, generating DKK 5.4 million in proceeds. The total share capital is now DKK 792,653,180 distributed across 79,265,318 shares.

09/04/2026, 2:20 AM • GlobeNewswire

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

Bavarian Nordic A/S announced a share capital increase of DKK 285,900 resulting from employees exercising warrants. The company issued 28,590 new shares at DKK 190.11 per share, generating DKK 5.4 million in proceeds. The total share capital is now DKK 792,653,180 comprising 79,265,318 shares.

09/04/2026, 2:20 AM • GlobeNewswire

Bavarian Nordic lancerer første del af nyt aktietilbagekøbsprogram

Bavarian Nordic A/S has commenced the first phase of a DKK 750 million share buyback program on September 1, 2026, with the initial phase targeting DKK 250 million in repurchases. The program, authorized by the general meeting and compliant with EU market abuse regulations, will be managed by Nordea and is intended to optimize the company's capital structure through subsequent cancellation of repurchased shares.

09/01/2026, 1:30 AM • GlobeNewswire

Bavarian Nordic Launches First Tranche of New Share Buy-Back Program

Bavarian Nordic A/S has launched the first tranche of a DKK 750 million share buy-back program on September 1, 2026, with the initial tranche comprising up to DKK 250 million. The program aims to adjust the company's capital structure through subsequent cancellation of repurchased shares and will be completed by October 30, 2026, with a maximum of 4,365,000 shares to be repurchased.

09/01/2026, 1:30 AM • GlobeNewswire

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic A/S reports insider transactions where CEO Paul Chaplin sold 90,000 shares at DKK 212.42 per share (DKK 19.1 million) on August 24, 2026, and Maria Tzatzaris, closely associated with Chaplin, sold 14,840 shares at DKK 207.91 per share (DKK 3.1 million) on August 21, 2026, both on Nasdaq Copenhagen.

08/25/2026, 3:00 PM • GlobeNewswire

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer

Bavarian Nordic A/S reported insider transactions on August 24-25, 2026, with CEO Paul Chaplin selling 90,000 shares at DKK 212.42 and a related party Maria Tzataris selling 14,840 shares at DKK 207.91. The company announced strong first half 2026 results and plans a new share buy-back program of up to DKK 750 million.

08/25/2026, 3:00 PM • GlobeNewswire

Bavarian Nordics chikungunyavaccine indsendt til myndighedsgodkendelse i Brasilien

Bavarian Nordic announced that its partner Eurofarma has submitted a marketing authorization application to Brazil's health authority Anvisa for CHIKV VLP, a chikungunya vaccine for individuals 12 years and older. This milestone represents a significant step in expanding vaccine access to one of the countries most affected by chikungunya, where over half of global cases and deaths occur.

07/13/2026, 9:00 AM • GlobeNewswire

Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

Eurofarma has submitted a marketing authorization application to Brazil's Anvisa for Bavarian Nordic's chikungunya vaccine (CHIKV VLP) for individuals 12 years and older. The submission marks a key milestone in their partnership and addresses Brazil's significant burden of chikungunya cases, which account for over half of global reported cases and deaths.

07/13/2026, 9:00 AM • GlobeNewswire

Bavarian Nordic – afslutning af aktietilbagekøbsprogram

Bavarian Nordic A/S has completed the third and final phase of its planned DKK 500 million share buy-back program for 2026, repurchasing approximately DKK 150 million worth of shares (820,607 shares at an average price of DKK 182.79). The company will retain these shares as treasury stock to optimize its capital structure. Following these transactions, Bavarian Nordic now holds 3,558,591 treasury shares, representing 4.49% of its share capital.

07/13/2026, 3:53 AM • GlobeNewswire

Bavarian Nordic – Completion of Share Buy-Back Program

Bavarian Nordic A/S has completed the third and final tranche of its 2026 share buy-back program, repurchasing approximately DKK 150 million worth of shares (820,607 shares at an average price of DKK 182.79). The company now holds 3,558,591 treasury shares, representing 4.49% of its share capital, which will be held for capital structure adjustment purposes.

07/13/2026, 3:53 AM • GlobeNewswire

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic A/S has completed share repurchases totaling DKK 120.5 million under its buy-back program initiated on June 2, 2026. The company acquired 664,764 shares at an average price of DKK 181.28, bringing total treasury shares to 3,402,748 (4.29% of share capital). The program runs through July 10, 2026, with a maximum budget of DKK 150 million.

07/06/2026, 3:56 AM • GlobeNewswire

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic A/S has completed share repurchase transactions totaling DKK 120.5 million under its buy-back program, acquiring 664,764 shares at an average price of DKK 181.28. The company now holds 3,402,748 treasury shares representing 4.29% of share capital. Additionally, Health Canada approved the company's chikungunya vaccine VIMKUNYA®.

07/06/2026, 3:56 AM • GlobeNewswire

Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram

Bavarian Nordic A/S reported completion of share repurchases totaling DKK 83.04 million under its DKK 150 million buy-back program initiated on June 2, 2026. The company has repurchased 462,119 shares at an average price of DKK 179.70, bringing total owned shares to 3,200,103 (4.04% of share capital). The program runs through July 10, 2026, in compliance with EU market abuse regulations.

06/29/2026, 2:36 AM • GlobeNewswire